From the DNA-methylation layer, PRDM16 (epigenetically silenced and associated with poor outcome) [38], ALK (previously indicated by altered gene expression in TCGA data and associated with survival in ACC patients) [39], and PPARG (whose agonists suppress ACC-cell proliferation in vitro) [40] emerged as top candidates. This evidence concerns the gene PRDM16 and adrenal cortex carcinoma.